Biosketch / Results /

Alan Weinstein

Clinical Associate Professor, Department of Ronald O. Perelman Department of Dermatology
Dermatology

Contact Info

718/434-5600
AlanS.WeinsteinAMD@nyumc.org

Education

1961-1962 — The Jewish Hospital of Brooklyn (Pediatrics), Residency Training
1964-1967 — NYU Medical Center (Dermatology), Residency Training

Cell-bound complement activation products in systemic lupus erythematosus: Comparison with anti-double-stranded DNA and standard complement measurements
Putterman, C; Furie, R; Ramsey-Goldman, R; Askanase, A; Buyon, J; Kalunian, K; Chatham, W W; Massarotti, E; Kirou, K; Jordan, N; Blanco, I; Weinstein, A; Chitkara, P; Manzi, S; Ahearn, J; O'Malley, T; Conklin, J; Ibarra, C; Barken, D; Dervieux, T. Cell-bound complement activation products in systemic lupus erythematosus: Comparison with anti-double-stranded DNA and standard complement measurements. Lupus science & medicine. 2014 01 Jun 2014;1(1):- e000056 (1906302)

Cell Bound Complement Activation Products Have Higher Sensitivity Than Serum C3 and C4 Levels in Systemic Lupus Erythematosus.
Ramsey-Goldman, Rosalind; Furie, Richard; Putterman, Chaim; Askanase, Anka; Buyon, Jill P; Kalunian, Kenneth; Chatham, WWinn; Massarotti, E; Kirou, Kyriakos A; Weinstein, A; Chitkara, Puja; Manzi, Susan; Ahearn, Joe; Wolover, Leilani; Conklin, John; O'Malley, Tyler; Ibarra, Claudia; Barken, Derren; Dervieux, Thierry. Cell Bound Complement Activation Products Have Higher Sensitivity Than Serum C3 and C4 Levels in Systemic Lupus Erythematosus. [Meeting Abstract]. Arthritis & rheumatology. 2014 OCT;66:S846-S847 (1444092)

Percutaneous gene therapy heals cranial defects
Layliev, J; Sagebin, F; Weinstein, A; Marchac, A; Szpalski, C; Saadeh, P B; Warren, S M. Percutaneous gene therapy heals cranial defects. Gene therapy. 2013 Sep;20(9):922-929 (519362)

The leukotriene antagonist zafirlukast as a therapeutic agent for atopic dermatitis
Carucci JA; Washenik K; Weinstein A; Shupack J; Cohen DE. The leukotriene antagonist zafirlukast as a therapeutic agent for atopic dermatitis. Archives of dermatology (1960). 1998 Jul;134(7):785-786 (7525)

Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study
Wigley, F M; Korn, J H; Csuka, M E; Medsger, T A Jr; Rothfield, N F; Ellman, M; Martin, R; Collier, D H; Weinstein, A; Furst, D E; Jimenez, S A; Mayes, M D; Merkel, P A; Gruber, B; Kaufman, L; Varga, J; Bell, P; Kern, J; Marrott, P; White, B; Simms, R W; Phillips, A C; Seibold, J R. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. Arthritis & rheumatism. 1998 Apr;41(4):670-677 (1382412)